ArticleRheumatology (Oxford, England)2021
Telemedicine in rheumatology: a reliable approach beyond the pandemic.
Article in Rheumatology (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Telehealth in rheumatology: the 2021 Arab League of Rheumatology Best Practice Guidelines.Rheumatology international · 2022Guideline
- Trial
- Patient satisfaction in a new model of nurse- and pharmacist-led virtual monitoring clinic in rheumatology practice.BMC rheumatology · 2026Article
- Telemedicine for the Care of Patients with Idiopathic Inflammatory Myopathies: Experience, Insights and Future Directions from the International Myositis Assessment and Clinical Studies Telemedicine Scientific Interest Group.Current rheumatology reports · 2024Article
- Telemedicine for Patients With Systemic Lupus Erythematosus in a Publicly Funded Hospital System: Retrospective Study.Interactive journal of medical research · 2024Article
- Article
- Patient perspectives on telemedicine use in rheumatology during the COVID-19 pandemic: survey results from the COVID-19 Global Rheumatology Alliance.Clinical rheumatology · 2024Article
- Key data elements for a successful pediatric rheumatology virtual visit: a survey within the PR-COIN network.Frontiers in pediatrics · 2024Article
- Patient Acceptability of Symptom Screening and Patient Education Using a Chatbot for Autoimmune Inflammatory Diseases: Survey Study.JMIR formative research · 2023Article
- Digital Approaches for Myositis.Current rheumatology reports · 2023Review
- The Attitude of Egyptian Patients with Autoimmune and Rheumatic Diseases towards Telemedicine.Medicina (Kaunas, Lithuania) · 2023Article
- Activities of Clinical Expertise and Research in a Rare Disease Referral Centre: A Place for Telemedicine beyond the COVID-19 Pandemic?Healthcare (Basel, Switzerland) · 2023Article
- Joining telehealth in rheumatology: a survey on the role played by personalized experience from patients' perspective.BMC health services research · 2023Article
- Review
- Impact of COVID-19 pandemic on the management of patients with RA: a survey of rheumatologists in six European countries.Rheumatology advances in practice · 2023Article
- A Thermographic Disease Activity Index for remote assessment of rheumatoid arthritis.RMD open · 2022Article
- Factors affecting patient satisfaction with outpatient rheumatology phone visits during the COVID-19 pandemic.Clinical rheumatology · 2022Article
- Lessons From the COVID-19 Pandemic to Improve the Health, Social Care, and Well-being of Minoritized Ethnic Groups With Chronic Conditions or Impairments: Protocol for a Mixed Methods Study.JMIR research protocols · 2022Article
- Telemedicine in the COVID-19 Era: A Narrative Review Based on Current Evidence.International journal of environmental research and public health · 2022Review
- Patients with rheumatic diseases are ready to use social media in clinical practice; what about rheumatologists? A cross-sectional survey.Rheumatology international · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe SARS-CoV-2 outbreak has imposed considerable restrictions on people's mobility, which affects the referral of chronically ill patients to health care structures. The emerging need for alternative ways to follow these patients up is leading to a wide adoption of telemedicine. We aimed to evaluate the feasibility of this approach for our cohort of patients with CTDs, investigating their attitude to adopting telemedicine, even after the pandemic.
methodsWe conducted a telephonic survey among consecutive patients referred to our CTD outpatients' clinic, evaluating their capability and propensity for adopting telemedicine and whether they would prefer it over face-to-face evaluation. Demographical and occupational factors were also collected, and their influence on the answers has been evaluated by a multivariate analysis.
resultsA total of 175 patients answered our survey (M/F = 28/147), with a median age of 62.5 years [interquartile range (IQR) 53-73]. About 80% of patients owned a device allowing video-calls, and 86% would be able to perform a tele-visit, either alone (50%) or with the help of a relative (36%). Telemedicine was considered acceptable by 78% of patients and 61% would prefer it. Distance from the hospital and patient's educational level were the strongest predictive factors for the acceptance of telemedicine (P < 0.05), whereas age only affected the mastering of required skills (P < 0.001).
conclusionTelemedicine is a viable approach to be considered for routine follow-up of chronic patients, even beyond the pandemic. Our data showed that older patients would be willing to use this approach, although a proper guide for them would be required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.